Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma
- 4 April 2019
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (14) , 1374-1377
Abstract
To the Editor: Recently, trials of adjuvant therapy for melanoma in which therapies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), or BRAF and MEK are assessed have reported positive results in terms of relapse-free survival and distant metastasis–free survival.1-4 The European Organization for Research and Treatment of Cancer (EORTC) 18071 trial1 compared ipilimumab with placebo in patients with resected stage III melanoma; the CheckMate 238 trial2 compared nivolumab with ipilimumab in patients with resected stage IIIB, IIIC, or IV melanoma; and the COMBI-AD trial (Nov. 9, 2017, issue)3,4 compared dabrafenib plus trametinib with placebo in patients . . .Keywords
This publication has 5 references indexed in Scilit:
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III MelanomaJournal of Clinical Oncology, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaNew England Journal of Medicine, 2017
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyNew England Journal of Medicine, 2016